Dupixent 200 MG/1.14 ML pen 1.14ML
Ended Awarded
- Contract number
- SPE2DB25FAWMZ
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $19,657
Award facts
- Contract value 100% obligated
- $19,657.19 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, was awarded a delivery order contract by the Defense Logistics Agency (DLA) on September 17, 2025, for the supply of Dupixent 200 mg/1.14 mL pen injections. The contract carries a ceiling value of $19,657.19 and is classified as a firm fixed-price delivery order with an ultimate completion date of September 18, 2025. The place of performance is listed as Conshohocken, Pennsylvania. This delivery order is issued under DMS Pharmaceutical Group's existing single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026, which authorizes the issuance of firm fixed-price delivery orders for pharmaceutical products supporting military health facilities worldwide.
The award represents no set-aside designation and reflects DMS Pharmaceutical Group's established role as a critical supplier in the federal pharmaceutical supply chain. The company leverages its woman-owned small business status to compete effectively in federal procurement while providing distribution of branded and generic prescription drugs, biologics, and medical consumables directly to Department of Defense healthcare sites. The delivery of Dupixent, a branded pharmaceutical product used in treating atopic dermatitis and other immunological conditions, demonstrates the contractor's capability to supply specialized medications required by military medical facilities.
Quick answers
Who was awarded contract SPE2DB25FAWMZ?
SPE2DB25FAWMZ was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 17, 2025.
How much is contract SPE2DB25FAWMZ worth?
The government has obligated $19,657 on SPE2DB25FAWMZ.
Is contract SPE2DB25FAWMZ an order under another contract?
Yes. SPE2DB25FAWMZ is a delivery order under SPE2DB24D2106, an indefinite delivery contract.
Was contract SPE2DB25FAWMZ competed?
The extent of competition for SPE2DB25FAWMZ was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award